Eli Lilly's $3.
8 Billion Bet on a New Approach to Depression Treatment Eli Lilly has made a bold move in the rapidly evolving market for treatment resistant depression and other severe psychiatric disorders by agreeing to acquire AtaiBeckley Inc.
for up to $3. 8 billion. The deal sends a clear signal that investors are placing their bets on innovative treatments that target the biological root of these conditions.